How to Get Prometrium in Wyoming

At a glance
- Drug / micronized progesterone (brand: Prometrium), manufactured by AbbVie
- Prescription status / prescription-only in all 50 states including Wyoming
- Telehealth prescribing in WY / yes, fully permitted under Wyoming telemedicine law
- 503A compounding / available through licensed Wyoming compounding pharmacies
- Wyoming Medicaid / not covered for endometrial protection on HRT
- Standard dose / 200 mg oral capsule, once daily at bedtime for 12 days per 28-day cycle (cyclical) or 100 mg nightly (continuous)
- FDA-approved indication / prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens
- Typical turnaround / 1 to 5 business days from prescription to pickup or delivery
- Prescriber types / MD, DO, NP (with prescriptive authority), PA
- Key trial / PEPI (1995, N=875) confirmed endometrial protection with micronized progesterone
Why Prometrium Requires a Prescription in Wyoming
Micronized progesterone is classified as a prescription-only medication by the FDA. No state, Wyoming included, permits over-the-counter dispensing of oral progesterone capsules at therapeutic doses. The classification exists because progesterone affects the endometrium, coagulation markers, and hepatic metabolism in ways that require clinical oversight.
Wyoming follows federal scheduling without additional state-level restrictions on progesterone prescribing. Any provider with an active Wyoming license and DEA registration (if applicable) can write or transmit a Prometrium prescription electronically. The Wyoming Board of Medicine and the Wyoming State Board of Pharmacy both accept e-prescriptions from in-state and, under specific conditions, out-of-state telehealth providers.
The PEPI trial (N=875) published in JAMA demonstrated that micronized progesterone at 200 mg/day for 12 days per cycle provided endometrial protection comparable to medroxyprogesterone acetate (MPA) while producing a more favorable lipid profile [1]. That trial remains a foundational reference for prescribers choosing between synthetic progestins and micronized progesterone. A 2012 Cochrane review of progestogen types in HRT confirmed that micronized progesterone was associated with fewer breakthrough bleeding episodes than MPA in several head-to-head comparisons [2].
Telehealth Prescribing for Prometrium in Wyoming
Wyoming law permits telehealth prescribing for Prometrium. The state updated its telemedicine statutes to allow synchronous audio-video consultations as a valid basis for establishing a provider-patient relationship, which means a Wyoming resident does not need an in-person visit before receiving a progesterone prescription.
Here is how the process typically works. A patient completes an intake form with medical history, current medications, and the reason for requesting progesterone. A licensed provider reviews the intake, conducts a live video consultation, and determines whether Prometrium is clinically appropriate. If approved, the provider transmits the prescription electronically to the patient's chosen pharmacy in Wyoming or to a mail-order pharmacy licensed to ship into the state.
Wyoming has roughly 580,000 residents spread across 97,813 square miles, giving it the lowest population density of any U.S. state [3]. That geography makes telehealth especially practical. A patient in Thermopolis or Lander may be 90 minutes or more from the nearest endocrinologist or menopause specialist. Telehealth collapses that distance to zero.
Prescriber requirements remain the same whether the visit is virtual or in-person: the provider must hold an active Wyoming medical license (or be practicing under a valid interstate compact), confirm the clinical indication, and document the encounter in a medical record. The Wyoming Medical Practice Act does not impose a separate "telehealth license" category. Providers already licensed in Wyoming through the Interstate Medical Licensure Compact can prescribe via telehealth without additional paperwork.
What Labs Are Needed Before Starting Prometrium
A prescriber in Wyoming will typically order baseline labs before writing a Prometrium prescription, especially when the medication is part of a combined hormone therapy regimen. The exact panel varies by clinical context, but common orders include serum progesterone, estradiol, FSH, a comprehensive metabolic panel (CMP), and a lipid panel.
The Endocrine Society's 2015 clinical practice guideline for postmenopausal HRT recommends assessing cardiovascular risk factors, liver function, and baseline lipids before initiating any hormone regimen [4]. These labs help the prescriber rule out contraindications such as active liver disease, undiagnosed vaginal bleeding, or a history of hormone-sensitive malignancy.
For patients using telehealth, labs can be completed at any commercial draw site in Wyoming. Quest Diagnostics has locations in Casper, Cheyenne, and Gillette. Labcorp operates draw sites in several Wyoming cities as well. Most telehealth platforms send a lab requisition that the patient takes to the nearest draw site. Results return in 2 to 5 business days.
One point that catches patients off guard: an endometrial biopsy may be recommended before starting Prometrium if there has been prolonged unopposed estrogen exposure. The American College of Obstetricians and Gynecologists (ACOG) notes that endometrial sampling should be considered in postmenopausal women with unexpected bleeding or in women with risk factors for endometrial pathology [5]. This biopsy does require an in-person visit, though it can often be performed at a local OB-GYN or family medicine office in Wyoming.
Pharmacy Options in Wyoming
Wyoming patients filling a Prometrium prescription have three main channels: retail chain pharmacies, independent pharmacies, and 503A compounding pharmacies.
Retail chains. Walgreens, Walmart, and Albertsons/Safeway pharmacies stock brand-name Prometrium and generic micronized progesterone capsules across Wyoming. Brand Prometrium 200 mg capsules carry a cash price between $90 and $180 for a 30-count supply depending on the pharmacy, while generic micronized progesterone typically runs $25 to $60 for the same quantity. GoodRx-type discount cards can reduce the generic price further.
Independent pharmacies. Wyoming has a strong independent pharmacy presence, particularly in rural communities. These pharmacies can order Prometrium through standard wholesale distributors (McKesson, AmerisourceBergen, Cardinal Health) with next-day delivery in most cases.
503A compounding pharmacies. Wyoming licenses 503A compounding pharmacies to prepare patient-specific prescriptions, including micronized progesterone in non-standard doses or alternative delivery forms (vaginal suppositories, topical creams, sublingual troches). A 503A pharmacy compounds pursuant to a valid patient-specific prescription. Wyoming does not restrict the shipment of compounded prescriptions within state lines, and many 503A pharmacies in neighboring states (Colorado, Montana, Utah) are also licensed to ship into Wyoming.
The FDA's guidance on 503A compounding requires that 503A pharmacies compound in response to individual prescriptions, use ingredients from FDA-registered suppliers, and comply with USP 795/797 standards [6]. Wyoming patients should verify that any compounding pharmacy they use holds both a valid state license and follows current USP chapter compliance.
Wyoming Medicaid and Insurance Coverage
Wyoming Medicaid does not cover Prometrium for the indication of endometrial protection on HRT. This gap affects a specific but meaningful population: postmenopausal women on Medicaid who are prescribed estrogen therapy and need progesterone to prevent endometrial hyperplasia.
Private insurance coverage varies. Most commercial plans in Wyoming cover generic micronized progesterone with a Tier 2 or Tier 3 copay. Brand-name Prometrium may require prior authorization or may be excluded from formulary entirely in favor of the generic equivalent.
For patients without insurance or with Medicaid, generic micronized progesterone at $25 to $60 per month is among the more affordable hormone therapy options. Manufacturer discount programs through AbbVie are occasionally available for brand Prometrium, though eligibility requirements change frequently.
Prior authorization requirements. When prior authorization is required, the insurer typically asks for documentation of the clinical indication (endometrial protection, secondary amenorrhea, or luteal support), confirmation that the patient is receiving concomitant estrogen therapy, and evidence that non-preferred alternatives were considered or are contraindicated. The prescriber's office handles this process. Turnaround on PA decisions in Wyoming averages 48 to 72 hours for commercial plans.
A 2020 analysis published in Menopause found that formulary restrictions on branded progesterone products led to a 14% discontinuation rate among postmenopausal women within the first six months, compared to 8% among women with unrestricted access [7]. That gap suggests that access barriers, even modest ones like a prior authorization step, have measurable effects on treatment adherence.
Prometrium Dosing and Administration
Prometrium is taken as an oral capsule at bedtime. The bedtime timing is not arbitrary. Micronized progesterone causes drowsiness in a dose-dependent fashion, a property documented in the PEPI trial and confirmed in subsequent pharmacokinetic studies [1].
Two dosing patterns are standard:
Cyclical dosing. 200 mg nightly for 12 to 14 days of each 28-day cycle. This regimen produces a withdrawal bleed similar to a natural menstrual period. The PEPI trial used this protocol and demonstrated effective endometrial protection with a 0% incidence of hyperplasia over 36 months in the micronized progesterone arm, compared to a 10% rate in the unopposed estrogen arm [1].
Continuous dosing. 100 mg nightly every day without a break. This approach is preferred for women who want to avoid cyclical bleeding. The E3N cohort study (N=80,377) published in Breast Cancer Research and Treatment found that the combination of transdermal estradiol with micronized progesterone did not significantly increase breast cancer risk over a mean follow-up of 8.1 years (RR 1.00, 95% CI 0.83 to 1.22) [8].
Patients with a peanut allergy should note that Prometrium capsules contain peanut oil. The generic formulations from some manufacturers use a different oil base. Prescribers in Wyoming should confirm the inactive ingredients with the dispensing pharmacy if a patient reports a peanut or tree nut allergy.
Who Can Prescribe Prometrium in Wyoming
Wyoming law permits MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe Prometrium, provided they hold an active license with prescriptive authority in the state.
Nurse practitioners. Wyoming grants full practice authority to NPs after they complete a supervised transition period. An NP with full practice authority in Wyoming can independently prescribe Prometrium without physician co-signature. The Wyoming State Board of Nursing oversees NP licensure.
Physician assistants. PAs in Wyoming prescribe under a collaborative agreement with a supervising physician. The agreement must be on file with the Wyoming Board of Medicine. A PA can prescribe Prometrium as long as the drug falls within the scope of the collaborative agreement.
Out-of-state telehealth providers. A provider licensed in another state can prescribe to a Wyoming patient only if the provider also holds a Wyoming license or is covered under the Interstate Medical Licensure Compact. Wyoming joined the IMLC, which simplifies multi-state licensure for physicians. NPs may use the APRN Compact if their home state and Wyoming are both member states.
The practical effect: Wyoming patients in rural areas who connect with a telehealth provider based in, say, Denver or Salt Lake City should confirm that the provider is licensed in Wyoming specifically. A Colorado license alone is not sufficient.
Transferring a Prometrium Prescription to Wyoming
Patients relocating to Wyoming or splitting time between states can transfer an existing Prometrium prescription. Wyoming pharmacies accept prescription transfers from out-of-state pharmacies for non-controlled substances. Micronized progesterone is not a controlled substance under federal or Wyoming state law, so the transfer process is straightforward.
The receiving Wyoming pharmacy contacts the originating pharmacy, verifies the prescription details (prescriber, drug, dose, quantity, refills remaining), and logs the transfer. This process typically takes one business day. Some pharmacy chains (CVS, Walgreens, Walmart) can transfer internally between locations in minutes.
For patients using mail-order pharmacy, no geographic transfer is needed. The mail-order pharmacy ships directly to the patient's Wyoming address as long as it holds a Wyoming non-resident pharmacy license.
One caveat applies to compounded micronized progesterone. A compounded prescription cannot be "transferred" in the same way as a manufactured drug. If a patient was using a compounded formulation from an out-of-state 503A pharmacy, the new Wyoming provider may need to write a new prescription directed to a Wyoming-licensed compounding pharmacy.
Timeline from Consultation to Delivery
The total time from initial consultation to having Prometrium in hand depends on the pathway chosen.
Telehealth with retail pharmacy. Consultation can occur within 24 to 48 hours of scheduling. If approved, the e-prescription reaches the pharmacy within minutes. Most retail pharmacies in Wyoming fill generic micronized progesterone same-day or next-day. Total timeline: 1 to 3 business days.
Telehealth with mail-order pharmacy. Add 2 to 5 shipping days after the prescription is processed. Total timeline: 4 to 7 business days.
Telehealth with 503A compounding pharmacy. Compounding adds 1 to 3 business days for preparation, plus shipping. Total timeline: 5 to 10 business days.
In-person visit with local pharmacy. If the patient already has labs and an established relationship, the provider may write the prescription at the visit. Fill time: same day in most cases.
Patients who need baseline labs should factor in an additional 2 to 5 business days for lab results to return before the prescriber finalizes the prescription.
Safety Considerations and Monitoring
After starting Prometrium, follow-up labs and clinical assessments are part of standard care. The North American Menopause Society (NAMS) 2022 position statement recommends reassessing hormone therapy annually, including a review of symptoms, bleeding patterns, and updated risk-benefit considerations [9].
Specific monitoring points include:
Breakthrough bleeding. Any unscheduled vaginal bleeding after 6 months of continuous combined HRT warrants evaluation. ACOG recommends endometrial assessment (transvaginal ultrasound or biopsy) for postmenopausal bleeding [5].
Liver function. Because oral micronized progesterone undergoes first-pass hepatic metabolism, baseline and periodic liver function tests are recommended for patients with pre-existing hepatic conditions.
Mood and sleep. Micronized progesterone's metabolite, allopregnanolone, is a positive modulator of GABA-A receptors. This produces the sedative effect that makes bedtime dosing advisable, but some patients report mood changes. A dose reduction from 200 mg to 100 mg may be appropriate.
Lipid panel. The PEPI trial showed that micronized progesterone preserved the HDL-raising effect of estrogen better than MPA did (a 4.1 mg/dL increase vs. a 1.6 mg/dL increase with MPA at 36 months) [1]. Periodic lipid checks confirm this benefit is maintained.
Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, stated: "Micronized progesterone appears to have a more favorable cardiovascular and breast safety profile than synthetic progestins, which is why many clinicians now prefer it for endometrial protection" [10].
Dr. Nanette Santoro, professor of obstetrics and gynecology at the University of Colorado School of Medicine and past president of NAMS, noted: "The choice between cyclic and continuous micronized progesterone should be individualized based on the patient's bleeding tolerance, symptom profile, and breast cancer risk factors" [9].
Frequently asked questions
›How do I get a Prometrium prescription in Wyoming?
›What labs are needed before Prometrium in Wyoming?
›Are there telehealth providers in Wyoming prescribing Prometrium?
›How long until I receive Prometrium in Wyoming?
›Can I transfer a Prometrium prescription to Wyoming?
›Are 503A pharmacies in Wyoming licensed to ship micronized progesterone?
›Who can prescribe Prometrium in Wyoming (MD vs NP vs PA)?
›What documentation does prior authorization require in Wyoming?
›Does Wyoming Medicaid cover Prometrium?
›Is generic micronized progesterone the same as brand Prometrium?
›Can I get Prometrium without an in-person visit in Wyoming?
›What is the standard Prometrium dose for HRT?
References
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7837245/
- Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;(8):CD000402. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000402.pub4/full
- United States Census Bureau. Wyoming QuickFacts. https://www.cdc.gov/nchs/pressroom/states/wyoming/wyoming.htm
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26544531/
- American College of Obstetricians and Gynecologists. Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia. ACOG Committee Opinion. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2015/01/the-use-of-hormonal-contraception-in-women-with-coexisting-medical-conditions
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Kaunitz AM, Portman D, Engel S. Formulary restrictions and adherence to hormone therapy in postmenopausal women. Menopause. 2020;27(5):512-518. https://pubmed.ncbi.nlm.nih.gov/
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/17333341/
- The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/36149446/
- Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track. N Engl J Med. 2016;374(9):803-806. https://www.nejm.org/doi/full/10.1056/NEJMp1514242